LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Затворен

13.88 0.36

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.73

Максимум

13.88

Ключови измерители
By Trading Economics
Приходи	-6.4M -20M
Продажби	-807K 71M
EPS	-0.13
Марж на печалбата	-28.24
Служители	624
EBITDA	-7.9M -14M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+45.32% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-282M 2B
Предишно отваряне	13.52
Предишно затваряне	13.88

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.05.2026 г., 08:24 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25.05.2026 г., 21:22 ч. UTC

Печалби

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Basic Materials Roundup: Market Talk

25.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Basic Materials Roundup: Market Talk

25.05.2026 г., 16:01 ч. UTC

Пазарно говорене

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25.05.2026 г., 14:43 ч. UTC

Пазарно говорене

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25.05.2026 г., 14:15 ч. UTC

Пазарно говорене

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25.05.2026 г., 13:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

25.05.2026 г., 12:58 ч. UTC

Пазарно говорене

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25.05.2026 г., 12:56 ч. UTC

Пазарно говорене

Печалби

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25.05.2026 г., 12:48 ч. UTC

Пазарно говорене

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25.05.2026 г., 12:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.05.2026 г., 12:34 ч. UTC

Пазарно говорене

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25.05.2026 г., 12:10 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Delivery Hero's Assets Look Strategic -- Market Talk

25.05.2026 г., 11:00 ч. UTC

Пазарно говорене

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25.05.2026 г., 10:19 ч. UTC

Пазарно говорене

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25.05.2026 г., 10:05 ч. UTC

Печалби

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25.05.2026 г., 10:04 ч. UTC

Печалби

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25.05.2026 г., 10:03 ч. UTC

Печалби

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25.05.2026 г., 10:02 ч. UTC

Печалби

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25.05.2026 г., 10:01 ч. UTC

Печалби

Tenaga Nasional 1Q Net Up 3.7% on Year

25.05.2026 г., 10:00 ч. UTC

Печалби

Tenaga Nasional 1Q Rev Up 6.6% on Year

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q EPS MYR0.1883

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q Rev MYR17.1B

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q Net MYR1.1B

25.05.2026 г., 09:38 ч. UTC

Пазарно говорене

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25.05.2026 г., 09:33 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

25.05.2026 г., 09:33 ч. UTC

Пазарно говорене

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25.05.2026 г., 08:55 ч. UTC

Пазарно говорене

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

45.32% нагоре

12-месечна прогноза

Среден 20.17 USD 45.32%

Висок 22 USD

Нисък 18 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.